Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat and LDAC in AML and MDS
NCT03459859Phase 1Completed
- Start
- May 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevonedistat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Started May 2018; status: completed.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03459859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459859.